Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle steroids and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Cytokinetics was founded in 1997 by James Spudich, Ronald Valli, James Sabry and Lawrence S.B Goldstein, four scientists at Stanford, UCSD, and UCSF. Operations began in 1998. Initially, cellular genetics focused on possible pharmacological goals and areas of application of drugs based on cellular proteins. Eventually, the company reduced its focus on muscular biology mechanisms. Cytokinetics develops muscle steroids and muscle inhibitors to improve muscle function in patients with cardiovascular and neuroorganic diseases. The company leads a muscle activation program is for a drug called mecarbil omecamtiv, currently being studied for a possible treatment for heart failure. Additional medications include reldesemtiv, a next-generation rapid skeletal skeletal tonic troponin, and CK-274, a small molecule myosin inhibitor. In 2004, the company completed its initial public offering (IPO). Amgen bought an option on mecarbil omecamtiv in 2006, and the two companies have since expanded their partnership several times. In January 2007, Cytokinetics appointed Robert I. Bloom as President and CEO. Prior to that, Blum has been involved in the company since its founding, with roles in business development and corporate development and R&D.In June 2013, Cytokinetics and Amgen expanded their licensing deal for mecarbil omecamtiv to include Japan. A week later, Cytokinetics ended a licensing and discovery deal with Astellas to look for a vulnerability treatment muscle and fatigue. In July 2020, Ji Xing Pharmaceuticals signed a financing deal with Cytokinetics, which included marketing rights to the drug designed to treat hypertrophic heart disease, CK-274, in China and some neighboring regions.